U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Hepatocellular Carcinoma

MedGen UID:
1699770
•Concept ID:
C5206563
•
Neoplastic Process

Definition

Hepatocellular carcinoma that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Hepatocellular Carcinoma

Professional guidelines

PubMed

Metronomic S-1 chemotherapy plus transcatheter arterial chemoembolization (TACE): a promising treatment of hepatocellular carcinoma refractory to TACE.
Huang W, You L, Yang S, Liu D, Liu M, Wang H, Wang P, Baikere P, Gu P, Abulikemu A, Yuan S, Fan X
J BUON 2016 Jul-Aug;21(4):909-916. PMID: 27685913
Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy.
Miyaki D, Aikata H, Kan H, Fujino H, Urabe A, Masaki K, Fukuhara T, Kobayashi T, Naeshiro N, Nakahara T, Kawaoka T, Hiramatsu A, Takahashi S, Ishikawa M, Kakizawa H, Awai K, Chayama K
J Gastroenterol Hepatol 2013 Dec;28(12):1834-41. doi: 10.1111/jgh.12311. PMID: 23808713
Hepatic intra-arterial cetuximab in combination with 5-fluorouracil and cisplatin as salvage treatment for sorafenib-refractory hepatocellular carcinoma.
Poggi G, Montagna B, Melchiorre F, Quaretti P, Delmonte A, Riccardi A, Tagliaferri B, Sottotetti F, Di Cesare P, Stella MG, Villani L, Zorzetto M, Greco G, Cornalba G, Bernardo G
Anticancer Res 2011 Nov;31(11):3927-33. PMID: 22110221

Recent clinical studies

Etiology

Immunotherapy combination with regorafenib for refractory hepatocellular carcinoma: A real-world study.
Tu X, Yang J, Zheng Y, Liang C, Tao Q, Tang X, Liu Z, Jiang L, He Z, Xie F, Zheng Y
Int Immunopharmacol 2022 Dec;113(Pt B):109401. Epub 2022 Nov 14 doi: 10.1016/j.intimp.2022.109401. PMID: 36395672
Efficacy of apatinib in patients with sorafenib-transarterial chemoembolization refractory hepatocellular carcinoma: a retrospective study.
Cao Y, Ouyang T, Xiong F, Kan X, Chen L, Liang B, Zheng C
Hepatol Int 2021 Oct;15(5):1268-1277. Epub 2021 Aug 20 doi: 10.1007/s12072-021-10198-3. PMID: 34415515
A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies.
Harding JJ, Do RK, Dika IE, Hollywood E, Uhlitskykh K, Valentino E, Wan P, Hamilton C, Feng X, Johnston A, Bomalaski J, Li CF, O'Reilly EM, Abou-Alfa GK
Cancer Chemother Pharmacol 2018 Sep;82(3):429-440. Epub 2018 Jul 3 doi: 10.1007/s00280-018-3635-3. PMID: 29971467Free PMC Article
Tumor Markers AFP, AFP-L3, and DCP in Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.
Hiraoka A, Ishimaru Y, Kawasaki H, Aibiki T, Okudaira T, Toshimori A, Kawamura T, Yamago H, Nakahara H, Suga Y, Azemoto N, Miyata H, Miyamoto Y, Ninomiya T, Hirooka M, Abe M, Matsuura B, Hiasa Y, Michitaka K
Oncology 2015;89(3):167-74. Epub 2015 May 12 doi: 10.1159/000381808. PMID: 25999038
Early evaluation of transcatheter arterial chemoembolization-refractory hepatocellular carcinoma.
Yamanaka K, Hatano E, Kitamura K, Iida T, Ishii T, Machimito T, Taura K, Yasuchika K, Isoda H, Shibata T, Uemoto S
J Gastroenterol 2012 Mar;47(3):343-6. Epub 2011 Dec 21 doi: 10.1007/s00535-011-0511-x. PMID: 22183859

Diagnosis

The excellent antitumor effect of apatinib alone as second-line therapy in a patient with sorafenib-refractory hepatocellular carcinoma: A case report.
Zhu H, Ma X, Zhao Y, Duo J
Medicine (Baltimore) 2018 Jun;97(25):e11214. doi: 10.1097/MD.0000000000011214. PMID: 29924049Free PMC Article
Tumor Markers AFP, AFP-L3, and DCP in Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.
Hiraoka A, Ishimaru Y, Kawasaki H, Aibiki T, Okudaira T, Toshimori A, Kawamura T, Yamago H, Nakahara H, Suga Y, Azemoto N, Miyata H, Miyamoto Y, Ninomiya T, Hirooka M, Abe M, Matsuura B, Hiasa Y, Michitaka K
Oncology 2015;89(3):167-74. Epub 2015 May 12 doi: 10.1159/000381808. PMID: 25999038
Early evaluation of transcatheter arterial chemoembolization-refractory hepatocellular carcinoma.
Yamanaka K, Hatano E, Kitamura K, Iida T, Ishii T, Machimito T, Taura K, Yasuchika K, Isoda H, Shibata T, Uemoto S
J Gastroenterol 2012 Mar;47(3):343-6. Epub 2011 Dec 21 doi: 10.1007/s00535-011-0511-x. PMID: 22183859
Transcatheter arterial infusion chemotherapy with a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma refractory to transcatheter arterial chemoembolization.
Iwasa S, Ikeda M, Okusaka T, Ueno H, Morizane C, Nakachi K, Mitsunaga S, Kondo S, Hagihara A, Shimizu S, Satake M, Arai Y
Jpn J Clin Oncol 2011 Jun;41(6):770-5. Epub 2011 Apr 1 doi: 10.1093/jjco/hyr037. PMID: 21459893

Therapy

Efficacy of apatinib in patients with sorafenib-transarterial chemoembolization refractory hepatocellular carcinoma: a retrospective study.
Cao Y, Ouyang T, Xiong F, Kan X, Chen L, Liang B, Zheng C
Hepatol Int 2021 Oct;15(5):1268-1277. Epub 2021 Aug 20 doi: 10.1007/s12072-021-10198-3. PMID: 34415515
A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies.
Harding JJ, Do RK, Dika IE, Hollywood E, Uhlitskykh K, Valentino E, Wan P, Hamilton C, Feng X, Johnston A, Bomalaski J, Li CF, O'Reilly EM, Abou-Alfa GK
Cancer Chemother Pharmacol 2018 Sep;82(3):429-440. Epub 2018 Jul 3 doi: 10.1007/s00280-018-3635-3. PMID: 29971467Free PMC Article
Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma.
Gabrielson A, Tesfaye AA, Marshall JL, Pishvaian MJ, Smaglo B, Jha R, Dorsch-Vogel K, Wang H, He AR
Cancer Chemother Pharmacol 2015 Nov;76(5):1073-9. Epub 2015 Oct 8 doi: 10.1007/s00280-015-2852-2. PMID: 26449224Free PMC Article
Is hepatic resection for recurrent or persistent hepatocellular carcinoma justified?
Kishi Y, Saiura A, Yamamoto J, Koga R, Seki M, Morimura R, Yoshioka R, Kokudo N, Yamaguch T
Hepatogastroenterology 2012 Oct;59(119):2255-9. doi: 10.5754/hge10505. PMID: 23435140
Hepatic intra-arterial cetuximab in combination with 5-fluorouracil and cisplatin as salvage treatment for sorafenib-refractory hepatocellular carcinoma.
Poggi G, Montagna B, Melchiorre F, Quaretti P, Delmonte A, Riccardi A, Tagliaferri B, Sottotetti F, Di Cesare P, Stella MG, Villani L, Zorzetto M, Greco G, Cornalba G, Bernardo G
Anticancer Res 2011 Nov;31(11):3927-33. PMID: 22110221

Prognosis

Efficacy of apatinib in patients with sorafenib-transarterial chemoembolization refractory hepatocellular carcinoma: a retrospective study.
Cao Y, Ouyang T, Xiong F, Kan X, Chen L, Liang B, Zheng C
Hepatol Int 2021 Oct;15(5):1268-1277. Epub 2021 Aug 20 doi: 10.1007/s12072-021-10198-3. PMID: 34415515
Tumor Markers AFP, AFP-L3, and DCP in Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.
Hiraoka A, Ishimaru Y, Kawasaki H, Aibiki T, Okudaira T, Toshimori A, Kawamura T, Yamago H, Nakahara H, Suga Y, Azemoto N, Miyata H, Miyamoto Y, Ninomiya T, Hirooka M, Abe M, Matsuura B, Hiasa Y, Michitaka K
Oncology 2015;89(3):167-74. Epub 2015 May 12 doi: 10.1159/000381808. PMID: 25999038
Is hepatic resection for recurrent or persistent hepatocellular carcinoma justified?
Kishi Y, Saiura A, Yamamoto J, Koga R, Seki M, Morimura R, Yoshioka R, Kokudo N, Yamaguch T
Hepatogastroenterology 2012 Oct;59(119):2255-9. doi: 10.5754/hge10505. PMID: 23435140
Early evaluation of transcatheter arterial chemoembolization-refractory hepatocellular carcinoma.
Yamanaka K, Hatano E, Kitamura K, Iida T, Ishii T, Machimito T, Taura K, Yasuchika K, Isoda H, Shibata T, Uemoto S
J Gastroenterol 2012 Mar;47(3):343-6. Epub 2011 Dec 21 doi: 10.1007/s00535-011-0511-x. PMID: 22183859
Hepatic intra-arterial cetuximab in combination with 5-fluorouracil and cisplatin as salvage treatment for sorafenib-refractory hepatocellular carcinoma.
Poggi G, Montagna B, Melchiorre F, Quaretti P, Delmonte A, Riccardi A, Tagliaferri B, Sottotetti F, Di Cesare P, Stella MG, Villani L, Zorzetto M, Greco G, Cornalba G, Bernardo G
Anticancer Res 2011 Nov;31(11):3927-33. PMID: 22110221

Clinical prediction guides

A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies.
Harding JJ, Do RK, Dika IE, Hollywood E, Uhlitskykh K, Valentino E, Wan P, Hamilton C, Feng X, Johnston A, Bomalaski J, Li CF, O'Reilly EM, Abou-Alfa GK
Cancer Chemother Pharmacol 2018 Sep;82(3):429-440. Epub 2018 Jul 3 doi: 10.1007/s00280-018-3635-3. PMID: 29971467Free PMC Article
Tumor Markers AFP, AFP-L3, and DCP in Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.
Hiraoka A, Ishimaru Y, Kawasaki H, Aibiki T, Okudaira T, Toshimori A, Kawamura T, Yamago H, Nakahara H, Suga Y, Azemoto N, Miyata H, Miyamoto Y, Ninomiya T, Hirooka M, Abe M, Matsuura B, Hiasa Y, Michitaka K
Oncology 2015;89(3):167-74. Epub 2015 May 12 doi: 10.1159/000381808. PMID: 25999038
Is hepatic resection for recurrent or persistent hepatocellular carcinoma justified?
Kishi Y, Saiura A, Yamamoto J, Koga R, Seki M, Morimura R, Yoshioka R, Kokudo N, Yamaguch T
Hepatogastroenterology 2012 Oct;59(119):2255-9. doi: 10.5754/hge10505. PMID: 23435140
Early evaluation of transcatheter arterial chemoembolization-refractory hepatocellular carcinoma.
Yamanaka K, Hatano E, Kitamura K, Iida T, Ishii T, Machimito T, Taura K, Yasuchika K, Isoda H, Shibata T, Uemoto S
J Gastroenterol 2012 Mar;47(3):343-6. Epub 2011 Dec 21 doi: 10.1007/s00535-011-0511-x. PMID: 22183859

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...